{"nctId":"NCT03525548","briefTitle":"A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","startDateStruct":{"date":"2018-08-03","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":113,"armGroups":[{"label":"TEZ/IVA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TEZ/IVA","Drug: IVA","Drug: Placebo"]},{"label":"VX-445/TEZ/IVA TC","type":"EXPERIMENTAL","interventionNames":["Drug: VX-445/TEZ/IVA","Drug: IVA","Drug: Placebo"]}],"interventions":[{"name":"VX-445/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","VX-445/tezacaftor/ivacaftor"]},{"name":"TEZ/IVA","otherNames":["VX-661/VX-770","tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Homozygous for the F508del mutation (F/F)\n* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height\n\nKey Exclusion Criteria:\n\n* Clinically significant cirrhosis with or without portal hypertension\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n* Solid organ or hematological transplantation\n\nOther protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.9"},{"groupId":"OG001","value":"10.4","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"1.8"},{"groupId":"OG001","value":"-43.4","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicate fewer symptoms and better health-related quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"2.0"},{"groupId":"OG001","value":"16.0","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Pre-Dose Concentration (Ctrough) of VX-445, TEZ, TEZ Metabolite (M1-TEZ), and IVA","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.84","spread":"2.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":"0.942"},{"groupId":"OG001","value":"1.60","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":"0.829"},{"groupId":"OG001","value":"1.89","spread":"0.974"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.84","spread":"1.71"},{"groupId":"OG001","value":"4.76","spread":"1.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.86","spread":"1.74"},{"groupId":"OG001","value":"5.28","spread":"2.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.652","spread":"0.399"},{"groupId":"OG001","value":"0.598","spread":"0.428"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.530","spread":"0.297"},{"groupId":"OG001","value":"0.652","spread":"0.542"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":52},"commonTop":["Cough","Haemoptysis","Headache","Sputum increased","Nasopharyngitis"]}}}